Baxter's Robert Parkinson - CEO Pay
Robert Parkinson - Baxter International
Total Compensation: $16M
Details: Parkinson received total compensation of $16 million, down form $17.6 million in 2007. According to SEC filings, Parkinson's compensation "reflects the role he plays in establishing Baxter's strategic agenda and long-range plan, meeting the challenges that arise in the day-to-day operations of a company as large and diverse as Baxter and leading the company in an increasingly challenging global economic environment."
The CEO's base salary came to $1.34 million, restricted stock awards totaled $5.54 million, options came to $5.3 million and cash compensation was $2.7 million. Perks leapt from $153,158 in 2007 to $212.326 in 2008.
Baxter News:
FDA finds 'final link' in heparin case
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: